Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Amanda C. Przespolewski, Scott Portwood & Eunice S. Wang. (2022) Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches. Leukemia & Lymphoma 63:4, pages 918-927.
Read now
Read now
Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli & Guido Kroemer. (2020) Trial watch: STING agonists in cancer therapy. OncoImmunology 9:1.
Read now
Read now
Julia M. Weiss, Marion V. Guérin, Fabienne Regnier, Gilles Renault, Isabelle Galy-Fauroux, Lene Vimeux, Vincent Feuillet, Elisa Peranzoni, Maxime Thoreau, Alain Trautmann & Nadège Bercovici. (2017) The STING agonist DMXAA triggers a cooperation between T lymphocytes and myeloid cells that leads to tumor regression. OncoImmunology 6:10.
Read now
Read now
D. W. Siemann, D. J. Chaplin & M. R. Horsman. (2017) Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation 35:8, pages 519-534.
Read now
Read now
Michael B Jameson & Michelle Head. (2011) Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). Expert Opinion on Drug Metabolism & Toxicology 7:10, pages 1315-1326.
Read now
Read now
Articles from other publishers (30)
Yiming Zhang, Zhijun Ouyang, Mengsi Zhan, Rui Yang, Yue Gao, Lulu Li, Rui Guo, Xiangyang Shi & Xueyan Cao. (2023) An Intelligent Vascular Disrupting Dendritic Nanodevice Incorporating Copper Sulfide Nanoparticles for Immune Modulation‐Mediated Combination Tumor Therapy. Small.
Crossref
Crossref
Charleen M. L. Chan Wah Hak, Antonio Rullan, Emmanuel C. Patin, Malin Pedersen, Alan A. Melcher & Kevin J. Harrington. (2022) Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Frontiers in Oncology 12.
Crossref
Crossref
Kriti Negi, Ashima Bhaskar & Ved Prakash Dwivedi. (2022) Progressive Host-Directed Strategies to Potentiate BCG Vaccination Against Tuberculosis. Frontiers in Immunology 13.
Crossref
Crossref
Manoj Chelvanambi, Ronald J Fecek, Jennifer L Taylor & Walter J Storkus. (2021) STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. Journal for ImmunoTherapy of Cancer 9:2, pages e001906.
Crossref
Crossref
Yijun Liu, Xin Lu, Nan Qin, Yuting Qiao, Shuaishuai Xing, Wenyuan Liu, Feng Feng, Zongliang Liu & Haopeng Sun. (2021) STING, a promising target for small molecular immune modulator: A review. European Journal of Medicinal Chemistry 211, pages 113113.
Crossref
Crossref
Haile Fentahun Darge, Endiries Yibru Hanurry, Yihenew Simegniew Birhan, Tefera Worku Mekonnen, Abegaz Tizazu Andrgie, Hsiao-Ying Chou, Juin-Yih Lai & Hsieh-Chih Tsai. (2021) Multifunctional drug-loaded micelles encapsulated in thermo-sensitive hydrogel for in vivo local cancer treatment: Synergistic effects of anti-vascular and immuno-chemotherapy. Chemical Engineering Journal 406, pages 126879.
Crossref
Crossref
Marion V. Guerin, Fabienne Regnier, Vincent Feuillet, Lene Vimeux, Julia M. Weiss, Georges Bismuth, Gregoire Altan-Bonnet, Thomas Guilbert, Maxime Thoreau, Veronica Finisguerra, Emmanuel Donnadieu, Alain Trautmann & Nadège Bercovici. (2019) TGFβ blocks IFNα/β release and tumor rejection in spontaneous mammary tumors. Nature Communications 10:1.
Crossref
Crossref
João Ribeiro, Cláudia Veloso, Carla Fernandes, Maria Elizabeth Tiritan & Madalena M. M. Pinto. (2019) Carboxyxanthones: Bioactive Agents and Molecular Scaffold for Synthesis of Analogues and Derivatives. Molecules 24:1, pages 180.
Crossref
Crossref
Roser Pons-Cursach & Oriol Casanovas. 2019. Tumor Angiogenesis. Tumor Angiogenesis
183
208
.
Amir Daei Farshchi Adli, Rana Jahanban-Esfahlan, Khaled Seidi, Sonia Samandari-Rad & Nosratollah Zarghami. (2018) An overview on Vadimezan (DMXAA): The vascular disrupting agent. Chemical Biology & Drug Design 91:5, pages 996-1006.
Crossref
Crossref
Stefanie J. Hectors, Igor Jacobs, Jasper Lok, Johannes Peters, Johan Bussink, Freek J. Hoeben, Henk M. Keizer, Henk M. Janssen, Klaas Nicolay, Matthias C. Schabel & Gustav J. Strijkers. (2018) Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI. Cancer Research 78:6, pages 1561-1570.
Crossref
Crossref
Roser Pons-Cursach & Oriol Casanovas. 2017. Tumor Angiogenesis. Tumor Angiogenesis
1
25
.
Oriol Casanovas & Roser Pons-Cursach. 2017. Tumor Angiogenesis. Tumor Angiogenesis
1
25
.
El Bairi Khalid, EL-Meghawry EL-Kenawy Ayman, Heshu Rahman, Guaadaoui Abdelkarim & Agnieszka Najda. (2016) Natural products against cancer angiogenesis. Tumor Biology 37:11, pages 14513-14536.
Crossref
Crossref
Shanshan Chen & Shun Lu. (2015) Antiangiogenic agents combined with chemotherapy in non-small cell lung cancer. Oncology and Translational Medicine 1:2, pages 58-64.
Crossref
Crossref
Guang-Hua Yan, Xiao-Fang Li, Bing-Chen Ge, Xiu-Dong Shi, Yu-Fang Chen, Xue-Mei Yang, Jiang-Ping Xu, Shu-Wen Liu, Pei-Liang Zhao, Zhong-Zhen Zhou, Chun-Qiong Zhou & Wen-Hua Chen. (2015) Synthesis and anticancer activities of 3-arylflavone-8-acetic acid derivatives. European Journal of Medicinal Chemistry 90, pages 251-257.
Crossref
Crossref
Bruce C. Baguley, Qi Ding & Emma Richardson. (2014) Preliminary Evidence That High-Dose Vitamin C has a Vascular Disrupting Action in Mice. Frontiers in Oncology 4.
Crossref
Crossref
Elena Porcù, Roberta Bortolozzi, Giuseppe Basso & Giampietro Viola. (2014) Recent advances in vascular disrupting agents in cancer therapy. Future Medicinal Chemistry 6:13, pages 1485-1498.
Crossref
Crossref
Charlene M. Downey, Mehrnoosh Aghaei, Reto A. Schwendener & Frank R. Jirik. (2014) DMXAA Causes Tumor Site-Specific Vascular Disruption in Murine Non-Small Cell Lung Cancer, and like the Endogenous Non-Canonical Cyclic Dinucleotide STING Agonist, 2′3′-cGAMP, Induces M2 Macrophage Repolarization. PLoS ONE 9:6, pages e99988.
Crossref
Crossref
Margaret Folaron, James Kalmuk, Jaimee Lockwood, Costakis Frangou, Jordan Vokes, Steven G. Turowski, Mihai Merzianu, Nestor R. Rigual, Maureen Sullivan-Nasca, Moni A. Kuriakose, Wesley L. HicksJr.Jr., Anurag K. Singh & Mukund Seshadri. (2013) Vascular priming enhances chemotherapeutic efficacy against head and neck cancer. Oral Oncology 49:9, pages 893-902.
Crossref
Crossref
Z G Fridlender, A Jassar, I Mishalian, L-CS Wang, V Kapoor, G Cheng, J Sun, S Singhal, L Levy & S M Albelda. (2013) Using macrophage activation to augment immunotherapy of established tumours. British Journal of Cancer 108:6, pages 1288-1297.
Crossref
Crossref
Martin Früh, Richard Cathomas, Marco Siano, Gregor Tscherry, Alfred Zippelius, Christoph Mamot, Andreas Erdmann, Fatima Krasniqi, Daniel Rauch, Mathew Simcock, Erika Küttel, Pierre Fustier & Miklos Pless. (2013) Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). Clinical Lung Cancer 14:1, pages 34-39.
Crossref
Crossref
Andrea T. Hooper, Frank Loganzo, Chad May & Hans-Peter Gerber. 2013. Natural Products and Cancer Drug Discovery. Natural Products and Cancer Drug Discovery
17
38
.
Bruce C Baguley & Mark J McKeage. (2012) Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence. Clinical Investigation 2:10, pages 985-993.
Crossref
Crossref
Eunice S. Wang, Roberto Pili & Mukund Seshadri. (2012) Modulation of Chemotherapeutic Efficacy by Vascular Disrupting Agents: Optimizing the Sequence and Schedule. Journal of Clinical Oncology 30:7, pages 760-761.
Crossref
Crossref
M. Pons-Salort, B. van der Sanden, A. Juhem, A. Popov & A. Stéphanou. (2012) A Computational Framework to Assess the Efficacy of Cytotoxic Molecules and Vascular Disrupting Agents against Solid Tumours. Mathematical Modelling of Natural Phenomena 7:1, pages 49-77.
Crossref
Crossref
Patricia M. LoRusso, Scott A. Boerner & Sally Hunsberger. (2011) Clinical Development of Vascular Disrupting Agents: What Lessons Can We Learn From ASA404?. Journal of Clinical Oncology 29:22, pages 2952-2955.
Crossref
Crossref
Wenkui Li, Hui Lin, Harold T. Smith & Francis L.S. Tse. (2011) Developing a robust ultrafiltration-LC–MS/MS method for quantitative analysis of unbound vadimezan (ASA404) in human plasma. Journal of Chromatography B 879:21, pages 1927-1933.
Crossref
Crossref
Christoph Oehler, Joseph A. O'Donoghue, James Russell, Pat Zanzonico, Sylvie Lorenzen, C. Clifton Ling & Sean Carlin. (2011)
18
F-Fluromisonidazole PET Imaging as a Biomarker for the Response to 5,6-Dimethylxanthenone-4-Acetic Acid in Colorectal Xenograft Tumors
. Journal of Nuclear Medicine 52:3, pages 437-444.
Crossref
Crossref
Wenyin Shi & Dietmar W. Siemann. 2011. Advances in Radiation Oncology in Lung Cancer. Advances in Radiation Oncology in Lung Cancer
17
41
.